换一批Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
第一作者：
D,Rayson
第一单位：
Department of Medical Oncology, Dalhousie University, Halifax, Nova Scotia, Canada. daniel.rayson@cdha.nshealth.ca
作者：
医学主题词
蒽环类(Anthracyclines);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);乳腺肿瘤(Breast Neoplasms);心肌疾病(Cardiomyopathies);化学疗法, 辅助(Chemotherapy, Adjuvant);临床试验, Ⅲ期(主题)(Clinical Trials, Phase III as Topic);剂量效应关系, 药物(Dose-Response Relationship, Drug);多柔比星(Doxorubicin);女(雌)性(Female);基因表达调控, 肿瘤(Gene Expression Regulation, Neoplastic);心脏功能试验(Heart Function Tests);人类(Humans);乳房切除术(Mastectomy);最大耐受剂量(Maximum Tolerated Dose);肿瘤分期(Neoplasm Staging);预后(Prognosis);随机对照试验(主题)(Randomized Controlled Trials as Topic);危险性评估(Risk Assessment);敏感性与特异性(Sensitivity and Specificity);存活率分析(Survival Analysis);治疗结果(Treatment Outcome)
DOI
10.1093/annonc/mdn292
PMID
18480068
发布时间
2022-03-11
- 浏览12
Annals of oncology
1530-9页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
